Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade

Area of Science:

• Neuro-oncology
• Virology
• Immunology

Background:

• Glioblastoma stem cells resist therapy, leading to inevitable recurrence.
• Zika virus (ZIKV) has shown potential in targeting glioblastoma stem cells.

Purpose of the Study:

• To investigate the immunological mechanisms behind ZIKV-mediated protection against glioblastoma.
• To evaluate the efficacy of ZIKV in combination with immunotherapy for glioblastoma treatment.

Main Methods:

• Zika virus (ZIKV) was introduced into brain tumors in a mouse model.
• Immune cell infiltration (CD8+ T cells, myeloid cells) was analyzed.
• CD8+ T cell depletion and anti-PD-1 antibody therapy were used to assess treatment efficacy.
• Tumor rechallenge experiments were performed to evaluate durable protection.

Main Results:

• ZIKV introduction increased CD8+ T cell and myeloid cell recruitment to the tumor microenvironment.
• CD8+ T cells were essential for ZIKV-mediated tumor clearance and survival benefits.
• Combination therapy with ZIKV and anti-PD-1 antibody significantly improved survival compared to monotherapy.
• ZIKV treatment induced durable protection against tumor recurrence, dependent on CD8+ T cells.

Conclusions:

• Oncolytic ZIKV therapy enhances anti-tumor immunity, particularly CD8+ T cell responses.
• Combination of oncolytic ZIKV with immunotherapies like anti-PD-1 antibodies shows promise for glioblastoma treatment.
• This approach may lead to new combination treatment strategies for adult glioblastoma patients.